Prothena Corporation plc (PRTA) Financial Analysis & Valuation | Quarter Chart
Prothena Corporation plc (PRTA)
PRTAPrice: $9.21
Fair Value: 🔒
🔒score
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the tre... more
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of nov... more
Description
Shares
| Market Cap | $495.80M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | IE | CEO | Gene G. Kinney |
| IPO Date | 2012-12-18 | CAGR | 0.4% |
| Employees | 163 | Website | www.prothena.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -0.01% | Total Yield | -0.01% |
PRTA chart loading...
Fundamentals
Technicals
| Enterprise Value | $130.98M | P/E Ratio | -2.03 |
| Forward P/E | -10.4 | PEG Ratio | — |
| P/S Ratio | 0.02 | P/B Ratio | 0.02 |
| P/CF Ratio | -0.02 | P/FCF Ratio | -0.02 |
| EPS | $-4.53 | EPS Growth 1Y | 110.48% |
| EPS Growth 3Y | 56.29% | EPS Growth 5Y | 103.91% |
| Revenue Growth 1Y | -91.16% | Gross Margin | 0.72% |
| Operating Margin | -21.66% | Profit Margin | -23.8% |
| ROE | -0.73% | ROA | -0.8% |
| ROCE | -0.85% | Current Ratio | 6.61 |
| Quick Ratio | 6.61 | Cash Ratio | 6.43 |
| Debt/Equity | 0.03 | Interest Coverage | — |
| Altman Z Score | -1.56 | Piotroski Score | 1 |